LACTOCOCCUS LACTIS GEN3013 STRAIN AND A COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAME

WIPO Patent Application WO/2019/199048

A1

The present invention relates to Lactococcus lactis GEN3013 strain and a composition for preventing or treating cancer and inflammatory diseases, comprising the same. Specifically, the Lactococcus lactis GEN3013 strain of the present invention exerts not only the effect of inhibiting the proliferation of cancer cells, reducing the motility of cancer cells, inhibiting angiogenesis, and increasing anti-cancer immune response, but also the effect of reducing the expression of inflammation factor, to prevent or treat cancers or inflammatory diseases. Further, Lactococcus lactis GEN3013 strain of the present invention exhibits more excellent anti-cancer effect when combined with other anti-cancer agents or antibodies for treating cancer.

PARK HAN SOO (KR)

PCT/KR2019/004262

October 17, 2019

April 11, 2019

Click for automatic bibliography generation  

GENOME & COMPANY (KR)
GWANGJU INST SCIENCE & TECH (KR)

C12N1/20; A23K10/16; A23L33/135; A61K35/744; A61P35/00; C12R1/46

KR20060026082A	2006-03-22
JP5871617B2	2016-03-01
KR100411198B1	2003-12-18

HAN, KYOUNG JUN ET AL.: "Anticancer and anti-inflammatory activity of probiotic Lactococcus lactis NK34", JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY, vol. 25, no. 10, 2015, pages 1697 - 1701, XP055645049
ZHANG, BO ET AL.: "Recombinant Lactococcus lactis NZ 9000 secretes a bioactive kisspeptin that inhibits proliferation and migration of human colon carcinoma HT-29 cells", MICROBIAL CELL FACTORIES, vol. 15, 2016, pages 1 - 11, XP055645052

KIM, Aera (KR)

View/Download PDF      PDF Help

Previous Patent: NON-AQUEOUS ELECTROLYTE FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY COMPRISING SAME

Next Patent: METHOD FOR CONTROLLING DEVICE IN WIRELESS COMMUNICATION SYSTEM AND DEVICE THEREFOR